Abstract Autosomal recessive inherited ataxias are a growing group of genetic disorders. We report two Italian siblings presenting in their mid-50s with difficulty in walking, dysarthria and progressive cognitive decline. Visual loss, ascribed to glaucoma, manifested a few years before the other symptoms. Brain MRI showed severe cerebellar atrophy, prevalent in the vermis, with marked cortical atrophy of both hemispheres. Exome sequencing identified a novel homozygous mutation (c.935G [ A;p.-Ser312Asn) in the ceroid neuronal lipofuscinosis type 5 gene (CLN5). Bioinformatics predictions and in vitro studies showed that the mutation was deleterious and likely affects ER-lysosome protein trafficking. Our findings support CLN5 hypomorphic mutations cause autosomal recessive cerebellar ataxia, confirming other reports showing CLN mutations are associated with adult-onset neurodegenerative disorders. We suggest CLN genes should be considered in the molecular analyses of patients presenting with adult-onset autosomal recessive cerebellar ataxia.
atrophy. Autosomal dominant forms typically have adultonset; conversely autosomal recessive ataxias usually have onset in childhood [10] . Clinically and neuroradiologically these latter diseases overlap with milder forms of Neuronal Ceroid Lipofuscinosis (NCLs), a group of progressive neurodegenerative disorders characterized by the intralysosomal accumulation in both neural and peripheral tissues of autofluorescent, electron-dense cytoplasmic lipopigments (bearing close resemblance to lipofuscin) [1] . Clinically, NCLs are characterized by a variable combination of visual impairment, cerebellar ataxia, drug-resistant progressive myoclonic epilepsy, behavioral disturbances, mental deterioration and early death [17] . NCLs are mainly transmitted with an autosomal recessive inheritance, though rare autosomal dominantly inherited forms have been described [11, 13, 23] , and largely occur in infancy or preteen ages.
At present, fourteen NCL forms are recognized, with 13 disease genes (named CLN) identified and more than 400 mutations reported (NCL Mutation Database: www.ucl.ac. uk/ncl/mutation).
Here we describe an autosomal recessive form of adultonset cerebellar ataxia associated with a novel CLN5 missense change in two siblings.
Materials and methods
We studied ATA-7-TO family originating from the NorthWest of Italy, in which the two affected siblings were born from first cousins parents. Genomic DNA was extracted from peripheral blood (Qiagen, Hilden, Germany) following the manufacturer instructions. Molecular testing was negative for SCA1, SCA2 and Friedreich Ataxia. Exome sequencing and data analysis were performed implementing a previously described procedure [9] (see supplement).
Validation of the mutation was performed by Sanger sequencing in all members of the family with primers designed to the exon 4 region of CLN5 (Reference sequence NM_006493, NP_006484.1).
Human wild-type CLN5-pCMV (a.a. 1-407, CLN5-wt) and CLN5-pCMV carrying the Finnish major diseasecausing mutation p.Tyr392* (CLN5-fin) have previously been described [16] . The CLN5-Ser312Asn vector was generated by in vitro mutagenesis, using the Quick Change site directed mutagenesis kit (Stratagene, La Jolla, CA, USA).
HEK293 cells were grown overnight on coverslips coated with gelatin 0.1 % in 24-well chambers and cultivated in DMEM 10 % FCS at 37°C and in presence of 5 % CO 2 . Transient transfection with vectors containing CLN5-wt, CLN5-fin, or CLN5-Ser312Asn cDNA was performed with Turbofect reagent (Thermo Fisher Scientific, Asheville, NC, USA) using the reported protocol [16] (see supplement).
Results
The 55-year-old proband (III-6 in Fig. 1a ) was a woman who presented with gait instability, dysarthria, and a mild cognitive deficit. Her past medical history had been unremarkable until she first sought neurological expert consultation after age 50 years because of unsteady gait. Neurologic examination at age 58 years was significant for a slight attention deficit, modest nystagmus with vertical component, dysarthric slurred speech, mild head tremor, and truncal ataxia. We also observed mild dysmetria and dysdiadochokinesia, an ataxic gait and posture, normal sensation, and brisk deep reflexes in the four limbs with normal plantar flexor response. Somatosensory evoked potentials, electroencephalogram (EEG), and nerve conduction velocities were all normal, as well as routine blood tests (including blood count, total cholesterol, alpha-fetoprotein and vitamin E levels).
Brain CT scan and MRI at age 58 years showed a marked cerebellar atrophy (more evident in the vermis than the hemispheres) with a severe bilateral cortical atrophymainly parietal and temporal-without focal lesions (Fig. 1b, c) .
At age 52 years, 3 years before recognition of her neurological symptoms, the patient complained visual problems that were initially attributed to glaucoma. Ophthalmological examination at age 58 years revealed a limited visual field in both eyes with a paracentral scotoma in the left eye. Fundoscopy disclosed a bilateral pale and excavated optic disc consistent with a severe galucoma but we could not exclude a previous lesion of the optic nerve.
At the age of 61 years, the patient showed a worsening of her dysarthria, could not walk without help, and showed a severe intentional tremor in the four limbs. Upon appropriate testing, including an age/educationadjusted Mini Mental State Examination (MMSE) score of 19.4/30, and a Montreal Cognitive Assessment score of 10/30, we also documented a more severe cognitive impairment with weakness especially in visual/spatial and executive tests, language, abstract symbolic reasoning, and action planning. Conversely, time and space orientation, short term memory, and calculation were relatively preserved.
Her elder brother (patient III-5 in Fig. 1a ) was first examined when he was 61 years old. He presented with gait problems and dysarthria since age 56 years with a slight worsening over the past 5 years. Neurological evaluation showed an ataxic-spastic gait, nystagmus in all directions, dysarthria with slurred speech, marked dysmetria in the lower limbs, and brisk, and symmetric deep reflexes in the limbs. Muscle strength and tone, as well as sensation, were not affected. A mild cognitive deficit was also evident at clinical examination, but the patient refused further neuropsychological testing.
As for her sister, case III-6, also had glaucoma. Brain MRI was not available.
We performed whole exome sequencing on III-5 and III-6 (71 9 and 68 9 coverage depth, respectively; sequencing statistics in Table S1 ). Assuming an autosomal recessive model of inheritance, we identified a single homozygous variant c.935G [ A on chr13:77574815 in the CLN5 gene, changing a Ser312 to Asn (NM_006493, OMIM *608102). This mutation was confirmed by Sanger sequencing (Fig. 1d) , in homozygosis in both affected siblings and in heterozygosis in the unaffected brother III-4.
Serine 312 is a highly evolutionary conserved amino acid in vertebrates and its change was predicted to be deleterious using different bioinformatics tools (Table S2 , figure S1 ). We evaluated the consequences of the p.Ser312Asn on CLN5 subcellular localization using Fig. 1 Pedigree, brain MRI, mutation and cellular analyses. a Pedigree of family ATA-7-TO suggested an autosomal recessive transmission due to parents consanguinity. b, c Axial and sagittal T1-weighted brain resonance magnetic images in patient II-5 at 58 years. A marked cerebellar hemispheric and a more severe vermian atrophy is present. Supratentorial atrophy is also evident. d Mutation c.935G [ A; p.Ser312Asn, affects a highly conserved amino acid (interspecies protein alignment is reported in figure S1 ). e, f, g HEK293 cells transfected with human wild-type CLN5, CLN5-fin and CLN5-Ser312Asn mutants, respectively. Immunostaining using rabbit antibody against CLN5 (1RmI-4) shows a diffuse punctate patter for wild-type protein consistent with its known lysosomal localization (e) [16] . Both mutants show a diffuse reticular staining, compatible with a ER retention (panels f and g). h and i Effect of cycloheximide treatment on CLN5 protein turnover (green). After 3 h incubation with cycloheximide wild-type CLN5 maintains a lysosomal localization, while CLN5-fin and CLN5-Ser312Asn mutants completely disappear from ER, as demonstrated by counter-staining with the ER marker PDI (in red) J Neurol (2015) 262:173-178 175 immunofluorescence microscopy after HEK293 transfection ( Fig. 1e-g ). Wild-type protein localized to lysosomal vesicles, as expected [16] , whereas both the CLN5-Ser312Asn and the CLN5-fin (Finnish mutation used as positive control) were retained in the Endoplasmic Reticulum (ER) compartment. Using cycloheximide, an inhibitor of cytoplasmic protein synthesis, we showed the complete disappearing of the fluorescence signal in cells carrying the CLN5-Ser312Asn indicating an intrinsic instability of the mutated proteins ( Fig. 1h-j) .
Discussion
Approximately 5 % of the CLN mutations have been associated with adult-onset neurological phenotypes (from 17 to 43 years) divided into three different subtypes: Kufs diseases, characterized by progressive myoclonus epilepsy and cognitive decline (Type A), or behavioral anomalies, dementia, motor dysfunction, ataxia and extrapyramidal and suprabulbar signs (Type B) [4, 18] ; adult NCLs which include autosomal dominant Parry disease due to DNJC5 mutations [13] and the recessive NCL type 11 associated with mutations in the progranulin gene [7] ( Table 1) . Ataxia is the first symptom in adult-onset Neuronal Ceroid Lipofuscinosis, often followed by rapid cognitive deterioration, epilepsy, and retinal degeneration.
Using exome sequencing, we identified a homozygous c.935G [ A (p.Ser312Asn) mutation in CLN5 in two adult siblings initially presenting ataxia. Both bioinformatics analysis and functional studies in HEK293 cells support the pathogenetic role of the mutation. While the wild-type CLN5 co-localize with lysosomes [16] , the p.Ser312Asn mutant protein was retained in the ER and did not reach the lysosome, in analogy with p.Tyr392*, a previously well characterized CLN5 protein change causing an infantileonset NCL in Finnish population. Therefore, our data further sustain the hypothesis that CLN5 mutations, including the one identified, impact the ER-lysosomal trafficking [15, 16] .
Remarkably, both our cases had the onset of their neurological manifestations after 50 years in the form of cerebellar ataxia with mild cognitive impairment, and represent the most late-onset cases associated with CLN mutations. Although features of glaucoma in both patients might be related to other processes, including aging, it is tempting to assume that ocular manifestations were part of the neurodegenerative process [24] . Most CLN5 mutations result in a classical disease with onset between 4 and 7 years, and few mutations are also associated with juvenile to early-adult onset. Three cases were described with onset at 17 years, carrying, respectively, the p.Tyr258Asp homozygous mutant [8] [24] . CLN5 disease-causing mutations are spread through the gene, and include missense, splicing, and nonsense alterations (www.ucl.ac.uk/ ncl/mutation). We hypothesize that the amino acid position and/or the chemical-physical change seen in our patients behaves as hypomorphic because it has a less severe impact on the protein function as compared to the other CLN5 variants.
TPP1, whose canonical mutations cause NCL2, has also been recently associated with autosomal recessive ataxia SCAR7 [20] , suggesting the existence of a novel category of adult-onset diseases associated with CLN mutations, presenting with cerebellar ataxia and progressive cognitive decline.
These data indicate that CLN2 and CLN5 may be suspected in case of adult-onset autosomal recessive cerebellar ataxia, and foresees the identification of further CLN involved in adult-onset phenotypes.
